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Abstract
Background: Mild gestational diabetes is a common complication of pregnancy, affecting up to 9%
of pregnant women. Treatment of mild GDM is known to reduce adverse perinatal outcomes such
as macrosomia and associated birth injuries, such as shoulder dystocia, bone fractures and nerve
palsies. This study aimed to compare the plasma glucose concentrations and serum insulin, leptin
and adiponectin in cord blood of babies of women (a) without gestational diabetes mellitus (GDM),
(b) with mild GDM under routine care, or (c) mild GDM with treatment.
Methods: 95 women with mild GDM on oral glucose tolerance testing (OGTT) at one tertiary
level maternity hospital who had been recruited to the ACHOIS trial at one of the collaborating
hospitals and randomised to either Treatment (n = 46) or Routine Care (n = 49) and Control
women with a normal OGTT (n = 133) were included in the study. Women with mild GDM
(treatment or routine care group) and OGTT normal women received routine pregnancy care. In
addition, women with treated mild GDM received dietary advice, blood glucose monitoring and
insulin if necessary.
The primary outcome measures were cord blood concentrations of glucose, insulin, adiponectin
and leptin.
Results: Cord plasma glucose was higher in women receiving routine care compared with control,
but was normalized by treatment for mild GDM (p = 0.01). Cord serum insulin and insulin to
glucose ratio were similar between the three groups. Leptin concentration in cord serum was
lower in GDM treated women compared with routine care (p = 0.02) and not different to control
(p = 0.11). Adiponectin was lower in both mild GDM groups compared with control (Treatment p
= 0.02 and Routine Care p = 0.07), while the adiponectin to leptin ratio was lower for women
receiving routine care compared with treatment (p = 0.08) and control (p = 0.05).
Conclusion: Treatment of women with mild GDM using diet, blood glucose monitoring and
insulin if necessary, influences the altered fetal adipoinsular axis characteristic of mild GDM in
pregnancy.
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Background
Mild gestational diabetes is a common complication of
pregnancy, affecting up to 9% of pregnant women [1]. Sig-
nificant maternal, fetal and neonatal morbidities are asso-
ciated with disturbances of glucose homeostasis in
pregnancy. Gestational diabetes mellitus (GDM)
increases the risk of macrosomia and associated birth
injuries, such as shoulder dystocia, bone fractures and
nerve palsies. Treatment of mild GDM is known to reduce
these adverse perinatal outcomes [2]. Longer-term adverse
health effects on offspring born to mothers with GDM
include obesity [3] and impaired intellectual develop-
ment [4].
GDM and diabetes mellitus result from insulin resistance
and inadequate compensatory insulin secretion. Together
these reduce insulin stimulation of glucose uptake by skel-
etal muscle, reduce inhibition of glucose release by liver,
and reduce insulin suppression of lipolysis and amino
acid turnover [5]. In GDM, these disturbances in insulin
action increase the concentrations of glucose and other
nutrients such as lipids and amino acids in maternal
blood, and also increase their transfer to the fetus [5]. This
combined with increased production of anabolic hor-
mones and growth factors, including insulin within the
fetus, promote fetal growth, resulting in macrosomia and
birth complications. These metabolic changes and endo-
crine adaptations in the fetus may also contribute to
longer-term complications such as obesity.
Maternal GDM, maternal obesity or being large or small
at birth predicts an increased risk of glucose intolerance or
diabetes in childhood, adolescence and adulthood
[3,6,7]. This may be mediated in part by an increased pro-
pensity to obesity from infancy onwards [5,6]. Adipose
tissue is an endocrine tissue, which secretes cytokines,
such as leptin, and TNF-alpha, IL-6, which are insulin
antagonistic, and adiponectin, which is insulin sensitizing
[8]. The adipoinsular axis regulates growth, appetite,
energy expenditure, body composition and metabolism
postnatally [8]. Increased adiposity increases plasma con-
centrations of leptin, and other adipocytokines [8], and
decreases that of adiponectin [9-11]. Diabetes in preg-
nancy increases concentrations of leptin in cord blood,
which correlate with increased fetal fat mass, but whether
this occurs in GDM is not known [12-14]. Adiponectin is
also present in cord blood, [15,16], but the impact of
GDM treatment on adiponectin in cord blood and the
effect of treatment of GDM on adipocytokines on both
leptin and adiponectin are also unknown.
The study reported here was therefore undertaken to char-
acterise the effects of mild GDM and treatment with diet,
blood glucose monitoring, and insulin therapy if required
on markers of adiposity and the adipoinsular axis in the
fetus. The latter reflect the intrauterine environment and
the fetal response to this and are possible predictors of
longer-term outcomes, such as risk of obesity, insulin
resistance and diabetes in childhood and adolescence [6].
It was hypothesized that maternal GDM increases cord
blood concentrations of glucose, insulin and leptin, but
decreases concentrations of adiponectin; and that treat-
ment of GDM with maternal dietary advice, blood glucose
monitoring and insulin therapy if required, would par-
tially prevent these consequences for the newborn baby.
The aims of this study were to measure cord blood plasma
glucose, cord blood serum insulin, leptin and adiponectin
concentrations, and to determine the insulin to glucose
and adiponectin to leptin ratios in cord blood of babies of
three groups of pregnant women at one of the collaborat-
ing hospitals for the Australian Carbohydrate Intolerance
Study in Pregnant Women (ACHOIS) trial; women with-
out GDM (Control); women with mild GDM women
receiving routine obstetric care (Routine Care), and
women with mild GDM receiving treatment of dietary
advice, blood glucose monitoring and insulin therapy if
required (Treatment).
Methods
Cord blood was collected from women randomised to the
ACHOIS trial at one of the collaborating centres, the
Women's and Children's Hospital (WCH), Adelaide, Aus-
tralia. Women in the ACHOIS trial had mild gestational
diabetes mellitis on oral glucose tolerance test (defined by
a 75 g OGTT fasting venous plasma glucose <7.8 mmol/1
and/or 2 hour ≥7.8 mmol/L and ≤ 11.0 mmol/1 between
24 – 346 weeks gestation [17]). Ninety-five of the 157
women randomised to the ACHOIS trial at the WCH gave
written informed consent to participate in this study and
cord blood samples were able to be collected during the
study period. Forty-six women had been randomised to
the Treatment Group and received dietary advice, blood
glucose monitoring and insulin as necessary as recom-
mended by clinical practice guidelines [18], and 49
women had been randomised to the Routine Care group
and received routine pregnancy care. At the WCH glucose
concentrations are not routinely monitored during labour
in women with GDM and no glucose infusion is routinely
given. Details of the methodology used in the ACHOIS
trial have been reported previously [2]. A Control group of
133 women with a normal OGTT was also recruited from
the WCH during the time course of this study and gave
written informed consent to participate. The Control
group received routine pregnancy care. Approval for the
study was given by the Institutional Ethics Committee.
Cord blood samples were collected at birth by delivery
suite staff. The cord was milked to produce a sample ofBMC Pediatrics 2007, 7:18 http://www.biomedcentral.com/1471-2431/7/18
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arterial and venous blood, and was placed in tubes con-
taining sodium fluoride for glucose analysis, and tubes
containing clot retraction accelerator for serum analysis of
insulin, leptin and adiponectin. Samples were centrifuged
after collection at 5000 rpm for 10 minutes at 4°C.
Samples were assayed blind. Plasma glucose concentra-
tions were measured in duplicate using the Beckman SYN-
CHRON CX Systems assay using hexokinase and were
accurate in the range of 0.3–38.8 mmol/l. Serum insulin,
leptin and adiponectin concentrations were measured
using commercially available radioimmunoassay kits spe-
cific for the human hormones, obtained from Linco
Research Pty Ltd. Iodine-125 activity was measured on the
Wallac 1261 Multigamma Gamma Counter.
Power calculation
In order to detect a difference in serum adiponectin con-
centrations of 4.3 ng/mL between the two GDM groups
and the Control group, and of 5.2 ng/mL between the two
GDM groups, a sample size of 47 women for each of the
GDM groups and 132 women in the Control group was
required, with an estimated standard deviation of 8.9,
using a two-sided significance level of 5% and power of
80%.
Statistical analysis
Statistical analysis of glucose and hormone parameters
was carried out using SAS Software (SAS Institute Inc.,
USA). Data that were not normally distributed were log-
transformed, and were used for statistical analysis to
approximate normal distributions. Analysis of variance
was used to compare outcomes among treatment groups.
Initial analyses were unadjusted. Adjustments were then
made where appropriate for parity, gestational age at
birth, fetal sex, smoking, birth weight and maternal body
mass index. Statistical significance was defined as p <
0.05.
Results
The maternal characteristics at entry to the study in the
different study groups were similar (Table 1). Four
women in the Treatment group received insulin therapy in
the antenatal period and one woman in the Routine Care
group. There were no differences in mode of birth
between the groups.
Cord blood plasma glucose
Plasma glucose was increased by about 10% in babies in
the Routine Care group, compared with those in the Con-
trol group (p = 0.01) (Table 2). No difference was detected
in plasma glucose between babies in the Treatment and
Control groups, or between babies in the Treatment and
Routine Care groups. However, after adjustment for par-
ity, smoking, gestational age at birth and fetal sex, babies
in both GDM (Treatment and Routine Care) groups had
increased plasma glucose (+~10%) compared with babies
in the Control group (Table 3).
Cord blood serum insulin and serum insulin/plasma glucose 
ratio (Tables 2 &3)
No differences were detected between the three study
groups in either cord blood serum insulin or serum insu-
lin/glucose ratios in unadjusted or adjusted analyses
(adjusted for parity, smoking, gestational age at birth,
fetal sex, birth weight or maternal body mass index).
Cord blood serum adiponectin
No difference was detected in serum adiponectin between
babies in the Routine Care group and the Control group
(p = 0.07) (Table 2). Babies of women in the Treatment
group had around 16% lower serum adiponectin com-
pared with the Control group (p = 0.02). No difference
was detected between serum adiponectin in babies of
women in the Treatment group and the Routine Care
group.
After adjustment for parity, smoking, gestational age at
birth, fetal sex and maternal body mass index, serum adi-
Table 1: Maternal Characteristics at Study Entry
Mild GDM Not GDM
Treatment Group Routine Care Group Control Group
Characteristic n = 46 n = 49 n = 133
Maternal Age (years) 31.7 5.2 30.1 4.4 29.2 5.5
Parity*
0 25 54.3 32 65.3 74 55.6
1–3 20 43.5 16 32.7 55 41.4
4 + 1 2.2 1 2.0 4 3.0
BMI (kg/m2)† 26 23.9–32.0 25.8 22.8–29.4 24.9 22.4–29.1
Smoking* 6 13.0 5 10.2 26 19.5
Figures are mean and standard deviation, number and percentages*, or median and interquartile range†.BMC Pediatrics 2007, 7:18 http://www.biomedcentral.com/1471-2431/7/18
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ponectin was around 15% lower in the Routine Care
group (p = 0.04), and around 23% lower in the Treatment
group (p = 0.01) than in the Control group. Serum adi-
ponectin was similar in both GDM groups. Further adjust-
ment for birth weight did not alter these outcomes (Table
3).
Cord blood serum leptin
Leptin concentrations were around 22% higher in cord
blood in the Routine Care group compared with the Treat-
ment group (p = 0.02) (Table 2). This difference persisted
after adjustment for parity, smoking, gestational age at
birth and sex. However, when adjustment was also made
for maternal body mass and birth weight no difference
between the two GDM groups could be detected. No dif-
ference in serum leptin was detected between babies in
the either of the GDM groups compared with the Control
group in unadjusted and adjusted analyses (adjusted for
parity, smoking, gestational age at birth, sex, maternal
body mass and birth weight) (Table 3).
Cord blood serum adiponectin/leptin ratio
The adiponectin/leptin ratio was around 38% lower in the
Routine Care group compared with the Control group (p
= 0.05), even when adjusted for parity, smoking, gesta-
tional age at birth and sex. (Table 2). However, this differ-
ence disappeared after adjustment for birth weight (p =
0.25) (Table 3). No difference was detected between the
adiponectin/leptin ratios in the Treatment group and the
Control group, or between the Treatment and Routine
Table 3: Cord Plasma/Serum concentrations of glucose and cytokines with additional adjustments for birth weight and maternal body 
mass index
GDM Not GDM
Treatment Group Routine Care Group Control Group
BW* BW+BMI* BW* BW+BMI* BW* BW+BMI*
Plasma Glucose (mmol/ml) 4.7 0.2 4.7 0.2 4.8 0.2+ 4.9 0.2+ 4.3 0.2 4.3 0.2
Serum Insulin (µU/ml)^ 2.0 0.2 2.1 0.2 2.1 0.2 2.1 0.2 2.0 0.1 2.0 0.1
Insulin to Glucose Ratio^ 0.6 0.2 0.6 0.2 0.6 0.2 0.5 0.2 0.6 0.1 0.5 0.1
Serum Adiponectin (ng/ml) 22.1 2.2+ 21.4 2.2+ 23.0 2.0+ 23.6 2.1+ 27.0 1.7 27.8 1.8
Serum Leptin (ng/ml)^ 2.4 0.1 2.4 0.1 2.5 0.1 2.5 0.1 2.4 0.1 2.5 0.1
Adiponectin to Leptin Ratio^ 0.7 0.2 0.6 0.2 0.6 0.2 0.6 0.2 0.8 0.1 0.8 0.1
Figures are mean, standard error
BW = Birth weight
BW + BMI = Birth weight + Maternal BMI
* Results also adjusted for parity, smoking, gestational age at birth and sex, with additional adjustment for BW and BMI
^ Statistical analysis was performed on log-transformed data
# p ≤ 0.05 versus GDM (Routine Care Group)
+ p ≤ 0.05 versus Control Group
Table 2: Cord/Plasma/Serum concentrations of glucose and cytokines with adjustments for parity, smoking, gestational age at birth 
and fetal sex
GDM Not GDM
Treatment Group Routine Care Group Control Group
Unadjusted Adjusted* Unadjusted Adjusted* Unadjusted Adjusted*
Plasma Glucose (mmol/ml) 4.8 0.2 4.7 0.2+ 5.0 0.2+ 4.8 0.2+ 4.5 0.1 4.3 0.2
Serum Insulin (µU/ml)^ 2.0 0.1 2.0 0.2 2.2 0.1 2.2 0.2 2.1 0.1 2.0 0.1
Insulin to Glucose Ratio^ 0.5 0.1 0.5 0.2 0.6 0.1 0.6 0.2 0.6 0.1 0.5 0.1
Serum Adiponectin (ng/ml) 23.0 1.7+ 21.8 2.1+ 24.3 1.5 23.2 2.0+ 27.5 1.0 26.8 1.7
Serum Leptin (ng/ml)^ 2.2 0.1 2.2 0.2 2.7 0.1# 2.6 0.1# 2.4 0.1 2.4 0.1
Adiponectin to Leptin Ratio^ 0.8 0.2 0.8 0.2 0.5 0.1+ 0.5 0.2+ 0.8 0.1 0.8 0.1
Figures are mean, standard error
^ Statistical analysis was performed on log-transformed data
* Results adjusted for parity, smoking, gestational age at birth and fetal sex
# p ≤ 0.05 versus GDM (Treatment Group)
+ p ≤ 0.05 versus Control GroupBMC Pediatrics 2007, 7:18 http://www.biomedcentral.com/1471-2431/7/18
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Care groups (p = 0.08) in adjusted or unadjusted analyses
(adjustment for parity, smoking, gestational age at birth
and sex and birth weight). Adjustment for maternal body
mass index had no effect on any of these outcomes.
Discussion
Mild maternal GDM alters cord blood concentrations of
glucose and adiponectin in the neonate, and these
changes can be partly reversed by treatment with dietary
advice, blood glucose monitoring and insulin therapy as
necessary. Babies of women with mild gestational diabe-
tes in the Routine Care group exhibited hyperglycaemia
and endocrine markers of increased adiposity, which is
characteristic of infants of diabetic mothers [5].
While babies of women with mild GDM in pregnancy
receiving routine care, had increased cord blood glucose
concentrations, the concentration of insulin in cord
serum and the insulin to glucose ratios were unchanged.
This suggests that the fetus experienced hyperglycaemia,
but did not respond with significant hyperinsulinaemia.
These findings are at odds with Roach et al [19], where
cord blood insulin was increased, however the current
study is substantially larger. Furthermore, babies of
women with mild GDM in the Routine Care group had
increased concentrations of leptin in cord serum com-
pared with babies of women in the Treatment group. con-
sistent with those reported for babies of mothers with
GDM [20] or with diabetes [12,14,21].
Leptin in cord blood is derived mainly from fetal adipose
tissue, although the placenta may contribute, and corre-
lates with birth weight and adipose tissue mass [22-24].
The increased cord blood leptin reported here with mild
GDM in the Routine Care group, therefore suggests
increased fetal fat deposition has occurred and may con-
tribute to the fetal macrosomia and dystocia, as seen in
GDM [13]. However, infant fat mass was not directly
assessed in the current study. Leptin acts centrally at the
hypothalamus to regulate appetite and to increase energy
expenditure [25]. If the hyperleptinaemia of the baby
born to women with untreated mild GDM is due substan-
tially to increased adiposity, it may persist for some time.
This could reduce appetite and food intake and might
contribute to the phenomenon of catch-down growth
seen in macrosomic infants following birth [26].
Babies of women with mild GDM in both Treatment and
the Routine Care group exhibited reduced cord blood
concentrations of adiponectin compared with those in the
Control Group, when the analysis was adjusted for parity,
smoking, gestational age at birth, fetal sex, birth weight,
and maternal body mass, as previously described in
babies born to diabetic women [27]. This has not been
examined previously in GDM. Increased adiposity in
these babies reduces circulating adiponectin as in the
adult [10,15], possibly as a result of increasing adipocyte
size, maturation and aging [28,29]. Stress-related hor-
mones and cytokines, such as glucocorticoids, catecho-
lamines and TNF-α can inhibit adiponectin production
however [30], and could be increased if these babies have
a higher metabolic rate and oxygen deficit chronically in
utero or during labor.
Similarly, the adiponectin to leptin ratio in cord blood
was reduced in babies of mothers with mild GDM in the
Routine Care Group further supporting a shift in the bal-
ance of adipocytokines to a profile which is more antago-
nistic of insulin action. While cord blood leptin levels are
increased in the cord blood of babies of diabetic women
[12] and women with GDM [31], the concentrations of
adiponectin and their ratio with leptin in cord blood have
not been characterized to date. This study has therefore
demonstrated that mild gestational diabetes in women
receiving routine care exposes the fetus to hyperglycaemia,
but not significant hyperinsulinaemia, but nevertheless,
results in markers of increased adiposity, hyperleptinae-
mia and reduced absolute and relative adiponectin levels.
This cytokine profile resembles that of infants of diabetic
mothers [12,14,21,27,32] and is one that might impair
insulin action in these neonates, altering subsequent
growth and metabolic control.
The range of concentrations of adiponectin in cord serum
reported here are comparable to those reported in other
studies of neonates from normal or diabetes pregnancies
[15,16] and similarly, are much higher than in adults [33].
Recent studies have shown that adiponectin circulates as
hexamers and large molecular weight multimers, which
appear to target different tissues in affecting insulin sensi-
tivity and metabolism [34]. The RIA used in the current
study measures total adiponectin and the impact of mild
GDM and treatment on various forms of adiponectin may
give more insight into the likely impact of any changes on
fetal and infant growth and metabolism. Because other
cytokines, IL-6 and TNF-alpha are strongly implicated in
adipocyte regulation of insulin action, it would be of
interest to examine these in the same cohorts to help iden-
tify mediators contributing to the outcomes for the neo-
natal adipoinsular axis.
This study has shown that treatment of women with mild
GDM did not lower cord blood glucose to that of women
without mild GDM. Treatment of GDM therefore does
not reduce exposure of the fetus to hyperglycaemia. How-
ever, treatment of women with mild GDM did lower con-
centrations of leptin in cord serum. This suggests that
some of the other potentially adverse consequences of
mild GDM for body composition may have been pre-
vented by treatment.BMC Pediatrics 2007, 7:18 http://www.biomedcentral.com/1471-2431/7/18
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Adaptations to an altered environment during intrauter-
ine development such as that induced by gestational dia-
betes during pregnancy, may lead to permanent changes
in the makeup of the human body [35]. Previous studies
[3,6,36] have shown that infants of women with GDM
have an increased risk of adolescent obesity and glucose
intolerance. A recent study reported that fasting plasma
adiponectin concentrations in adults could predict subse-
quent changes in insulin sensitivity over several years
[37]. A recent study reported lower concentrations of adi-
ponectin in young adults who had been born small for
gestational age [38]. Since low and high birth weight are
factors predisposing to gestational diabetes and type 2
diabetes in adult life [39], it will be important to deter-
mine if the partially normalized adiponectin-leptin ratio
in cord blood is associated with improved insulin sensi-
tivity or glucose tolerance later in life in these children.
The decreased cord blood adiponectin may be predictive
of insulin resistance in infancy and possibly childhood,
increasing the risk of developing related disorders.
Conclusion
In summary, babies of women with untreated mild GDM
compared with women without GDM have increased glu-
cose and reduced adiponectin, but unaltered insulin levels
and insulin to glucose ratio in cord blood. Treatment of
mild GDM with dietary advice, blood glucose monitoring
and insulin as necessary, did not lower cord blood glucose
or increase adiponectin, but did reduce cord blood leptin
and increase the adiponectin to leptin ratio.
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